We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid Influenza Diagnostic Tests Evaluated

By LabMedica International staff writers
Posted on 26 Dec 2012
Accurate diagnosis of influenza is critical for clinical management, infection control, and public health actions to minimize the burden of the disease. More...


Rapid influenza diagnostic tests (RIDTs) that detect the influenza virus nucleoprotein (NP) antigen are widely used in clinical practice for diagnosing influenza because they are simple to use and provide results within 15 minutes.

A collaboration between the US Centers of Disease Control (CDC; Atlanta, GA, USA), and the Medical College of Wisconsin (MCW; Milwaukee, WI, USA) evaluated RIDTs commercially available during the 2011–2012 influenza season. The CDC provided 16 influenza A and seven influenza B viruses to MCW. The concentration of influenza virus NP antigen was measured as μg/mL using isotope dilution tandem mass spectrometry. Swab samples or mock nasal wash specimens were prepared from several dilutions of each virus in saline.

The numbers of RIDTs that were positive, defined as at least two positive results of the three tests performed, at each dilution for each of the 23 influenza viruses were compared. The RIDTs overall had fewer positive results with viruses that had the lowest stock NP concentrations of less than 2 µg/mL. One RIDT, the SAS FluAlert Influenza A (SA Scientific; San Antonio, TX, USA) did not uniformly detect influenza A (H1N1)pdm09 (pH1N1) viruses or other influenza A viruses at high concentrations. Four RIDTs detected the majority of influenza B viruses in the third dilution samples, whereas only one RIDT, the BD Directigen EZ Flu A+B (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) detected at least 50% of all influenza A viruses in the third dilution samples.

Clinicians should be aware of the variability of RIDTs when interpreting negative results and should collect test samples using methods that can maximize the concentration of virus antigen in the sample, such as collecting adequate specimens using appropriate methods in the first 24 to 72 hours after illness onset. The study was published on November 2, 2012, in the Morbidity & Mortality Weekly Report.

Related Links:

US Centers of Disease Control
Medical College of Wisconsin
Becton, Dickinson and Company



Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Molecular Diagnostics

view channel
Image: Researchers identified eight new DNA pattern signatures that could help refine diagnostics and guide targeted therapy in breast cancer (image credit: 123RF)

Breast Cancer-Specific Signatures Link Genome Instability to Outcomes

Genomic instability is a hallmark of cancer, but most genomic analyses have relied on broad signatures shared across multiple malignancies, limiting their precision for individual tumor types.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.